<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04246190</url>
  </required_header>
  <id_info>
    <org_study_id>A65_03BE1921</org_study_id>
    <nct_id>NCT04246190</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-396</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-396 and Co-administration of CKD-501 and D759 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics and safety of CKD-396.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the
      Pharmacokinetics and Safety After Oral Administration of CKD-396 and Co-administration of
      CKD-501 and D759 in Healthy Adults
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 24, 2020</start_date>
  <completion_date type="Anticipated">July 16, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 10, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of CKD-501, D759 and CKD-396</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Maximum plasma concentration of CKD-501, D759 and CKD-396</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of CKD-501, D759 and CKD-396</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Area under the plasma concentration-time curve to last concentration of CKD-501, D759 and CKD-396</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Type2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-501 and D759
Period 2: CKD-396</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-396
Period 2: CKD-501 and D759</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-501 and D759</intervention_name>
    <description>Reference drug, CKD-501 1T and D759 1T, QD, PO</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-396</intervention_name>
    <description>Reference drug, CKD-396 1T, QD, PO</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult who is 19 ~ 55 years at the time of screening

          2. Body weight more than 55 kg for male and more than 50kg for female

          3. BMI more than 18.5 kg/m2 or less than 27.0 kg/m2

          4. Females must be menopause or surgical infertility

          5. Males who have consented to the use of appropriate pregnancy contraceptive methods up
             to 28 days after the last investigational product and not to provide sperm

          6. Subjects who voluntarily decided to participate and informed consent based upon
             understanding on the study.

        Exclusion Criteria:

          1. Subjects who have a history of clinically significant hepatic, renal, nervous, immune,
             respiratory, urinary, digestion, endocrine, hematooncology, cardiovascular systemic
             disease or psychosis disorder

          2. Subjects who have diabetic ketoacidoisis, diabetic coma, diabetic precoma, Type 1
             diabetes

          3. Subjects who have genetic problems such as galactose intolerance, Lapp lactase
             deficiency or glucose-galactose malabsorption

          4. Subjects who have a history of gastrointestinal disorders (Crohn's disease, ulcerative
             colitis, etc.) or surgery (except simple appendectomy or hernia surgery) that may
             affect the absorption of the drug

          5. Subjects who have a history of clinically significant hypersensitivity to drugs or
             additives, including components of the investigational product(lobeglitazone,
             sitagliptin) and same class drug with thiazolidinediones

          6. Subjects who have severe infectious disease and severe trauma before and after
             operation

          7. Subjects who are deemed unsuitable as subjects in the screening test performed within
             28 days before the administration of investigational product

               -  AST, ALT&gt; UNL(Upper Normal Limit)x1.25

               -  Total bilirubin &gt; UNL(Upper Normal Limit)x1.5

               -  eGFR (Estimated Glomerular Filtration Rate) &lt;60 mL/min/1.73m2 using the MDRD
                  (Modification of Diet in Renal Disease) formula

               -  Positive immunologic serological tests (hepatitis B test, hepatitis C test, human
                  immunodeficiency virus (HIV) test, syphilis test)

               -  After resting for more than 5 minutes, systolic blood pressure&gt; 150 mmHg or &lt; 90
                  mmHg, diastolic blood pressure&gt; 100 mmHg or &lt;50 mmHg

          8. Subjects who have had a history of drug abuse within one year of screening or have
             tested positive on urine drug screening test

          9. Pregnant or lactating women

         10. Subjects who have consistently excessively smoked or consumed caffeine or alcohol
             (caffeine:&gt; 5 cups / day, alcohol:&gt; 210 g / week, cigarettes:&gt; 10 cigarettes / day) or
             cannot stop smoking, consuming caffeine and alcohol during hospitalization

         11. Subjects who judged to able to affect in the study or in the subject's safety by the
             investigator for the following reasons

               -  Ethical-the-counter (ETC) drugs and herbal medicines within 14 days of the first
                  administration of the investigational drug.

               -  Over-the-counter (OTC) drugs, including health foods and vitamin preparations,
                  within 7 days of the first dose of the investigational product

         12. Subjects who have received the investigational product by participating in other
             clinical trials (including bioequivalence studies) within 180 days before the first
             dose of the investigational product (For biological agents, this may be based on a
             longer period of time, considering the half-life)

         13. Subjects who donated whole blood within 60 days before the first dose of the
             investigational product or donated component blood donation within 30 days

         14. Subjects who received a blood transfusion within 60 days before the first dose of the
             investigational product

         15. Subjects who were deemed to be inappropriate to participate in the study by the
             investigator judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Soo Park, Ph.D. M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Soo Park, Ph.D. M.D</last_name>
    <phone>+82-2-2228-0401</phone>
    <email>minspark@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yonsei University Severance Hospital</name>
      <address>
        <city>Soeul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Min Soo Park, Ph.D. M.D</last_name>
      <phone>+82-2-2228-0401</phone>
      <email>minspark@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Min Soo Park, Ph.D. M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

